Abstract:Objective: This study aimed to investigate the critical role of MDSCs in CRC immune suppression, focusing on the CSF1R and JAK/STAT3 signaling axis. Additionally, it assessed the therapeutic efficacy of LNCs@CSF1R siRNA and anti-PD-1 in combination. Methods: Single-cell transcriptome sequencing data from CRC and adjacent normal tissues identified MDSC-related differentially expressed genes. RNA-seq analysis comprehensively profiled MDSC gene expression in murine CRC tumors. LNCs@CSF1R siRNA nanocarriers effectively targeted and inhibited CSF1R. Flow cytometry quantified changes in MDSC surface markers post-CSF1R inhibition. RNA-seq and pathway enrichment analyses revealed the impact of CSF1R on MDSC metabolism and signaling. The effect of CSF1R inhibition on the JAK/STAT3 signaling axis was validated using Colivelin and metabolic assessments. Glucose and fatty acid uptake were measured via fluorescence-based flow cytometry. The efficacy of LNCs@CSF1R siRNA and anti-PD-1, alone and in combination, was evaluated in a murine CRC model with extensive tumor section analyses. Results: CSF1R played a significant role in MDSC-mediated immune suppression. LNCs@CSF1R siRNA nanocarriers effectively targeted MDSCs and inhibited CSF1R. CSF1R regulated MDSC fatty acid metabolism and immune suppression through the JAK/STAT3 signaling axis. Inhibition of CSF1R reduced STAT3 activation and target gene expression, which was rescued by Colivelin. Combined treatment with LNCs@CSF1R siRNA and anti-PD-1 significantly slowed tumor growth and reduced MDSC abundance within CRC tumors. Conclusion: CSF1R via the JAK/STAT3 axis critically regulates MDSCs, particularly in fatty acid metabolism and immune suppression. Combined therapy with LNCs@CSF1R siRNA and anti-PD-1 enhances therapeutic efficacy in a murine CRC model, providing a strong foundation for future clinical applications.

Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer.

Immunomodulation of Interleukin-34 and Its Potential Significance As a Disease Biomarker and Therapeutic Target

Biological functions and clinical implications of interleukin-34 in inflammatory diseases

IL-34 and CSF-1: similarities and differences

The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis

Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases

Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival

Cxxc Finger Protein 1 Positively Regulates Gm-Csf-Derived Macrophage Phagocytosis Through Csf2r Alpha-Mediated Signaling

Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations

Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications

CSF-1 Maintains Pathogenic but Not Homeostatic Myeloid Cells in the Central Nervous System During Autoimmune Neuroinflammation

Insights into CSF-1R Expression in the Tumor Microenvironment

Interactions Between Colon Cancer Cells and Tumor-Infiltrated Macrophages Depending on Cancer Cell-Derived Colony Stimulating Factor 1

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

Significance of IL-34 and SDC-1 in the pathogenesis of RA cells and preclinical models

The Critical Role Of Il-34 In Osteoclastogenesis

Sox13 and M2-like Leukemia-Associated Macrophages Contribute to Endogenous IL-34 Caused Accelerated Progression of Acute Myeloid Leukemia

Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis

Insights into the Role of CSF1R in the Central Nervous System and Neurological Disorders

iRhom2 regulates CSF1R cell surface expression and non-steady state myelopoiesis in mice

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment